These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 4121701)

  • 21. Complement C4-derived monocyte-directed chemotaxis-inhibitory factor. A molecular mechanism to cause polymorphonuclear leukocyte-predominant infiltration in rheumatoid arthritis synovial cavities.
    Matsubara S; Yamamoto T; Tsuruta T; Takagi K; Kambara T
    Am J Pathol; 1991 May; 138(5):1279-91. PubMed ID: 2024711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement component C5 is required for release of alveolar macrophage-derived neutrophil chemotactic activity.
    Robbins RA; Russ WD; Thomas KR; Rasmussen JK; Kay HD
    Am Rev Respir Dis; 1987 Mar; 135(3):659-64. PubMed ID: 3826892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement-derived leukotactic factors in inflammatory synovial fluids of humans.
    Ward PA; Zvaifler NJ
    J Clin Invest; 1971 Mar; 50(3):606-16. PubMed ID: 5545123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevation of serum chemotactic factor inactivator activity in rabbits induced by inflammation and chemotactic factor.
    Hupp JR; Despins AW; McCormick JR; Armstrong G; Kreutzer DL
    Am J Pathol; 1982 Dec; 109(3):277-82. PubMed ID: 7180941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defective regulation of chemotaxis in cirrhosis.
    Maderazo EC; Ward PA; Quintiliani R
    J Lab Clin Med; 1975 Apr; 85(4):621-30. PubMed ID: 1120929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and for tumor cells.
    Orr FW; Varani J; Kreutzer DL; Senior RM; Ward PA
    Am J Pathol; 1979 Jan; 94(1):75-83. PubMed ID: 569981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo production of chemotactic inhibitors by tumor cells.
    Cohen MC; Brozna JP; Ward PA
    Am J Pathol; 1979 Mar; 94(3):603-14. PubMed ID: 106732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet factor 4 is chemotactic for neutrophils and monocytes.
    Deuel TF; Senior RM; Chang D; Griffin GL; Heinrikson RL; Kaiser ET
    Proc Natl Acad Sci U S A; 1981 Jul; 78(7):4584-7. PubMed ID: 6945600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigenic identification of chemotactic factor inactivator in normal human serum and bronchoalveolar lavage fluid.
    Robbins RA; Rasmussen JK; Clayton ME; Gossman GL; Kendall TJ; Rennard SI
    J Lab Clin Med; 1987 Sep; 110(3):292-9. PubMed ID: 3611952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of human eosinophil polymorphonuclear leukocyte migration and function.
    Goetzl EJ
    Am J Pathol; 1976 Nov; 85(2):419-36. PubMed ID: 793410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.
    Ward PA; Berenberg JL
    N Engl J Med; 1974 Jan; 290(2):76-80. PubMed ID: 4855544
    [No Abstract]   [Full Text] [Related]  

  • 32. Chemotactic factor for tumor cells derived from the C5a fragment of complement component C5.
    Orr W; Phan SH; Varani J; Ward PA; Kreutzer DL; Webster RO; Henson PM
    Proc Natl Acad Sci U S A; 1979 Apr; 76(4):1986-9. PubMed ID: 287038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).
    Gitlin JD; Rosen FS; Lachmann PJ
    J Exp Med; 1975 May; 141(5):1221-6. PubMed ID: 1168693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antileukotactic properties of tumor cells.
    Brozna JP; Ward PA
    J Clin Invest; 1975 Sep; 56(3):616-23. PubMed ID: 239965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of action of the group A streptococcal C5a inactivator.
    Wexler DE; Chenoweth DE; Cleary PP
    Proc Natl Acad Sci U S A; 1985 Dec; 82(23):8144-8. PubMed ID: 3906656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A plasmin-split fragment of C'3 as a new chemotactic factor.
    Ward PA
    J Exp Med; 1967 Aug; 126(2):189-206. PubMed ID: 4226271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the C5 peptides chemotactic for leukocytes and tumor cells.
    Romualdez AG; Ward PA; Torikata T
    J Immunol; 1976 Nov; 117(5 Pt.2):1762-6. PubMed ID: 62790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leukotactic dystunction in sarcoidosis.
    Maderazo EG; Ward PA; Woronick CL; Kubik J; DeGraff AC
    Ann Intern Med; 1976 Apr; 84(4):414-9. PubMed ID: 769631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical quantitation of the chemotactic factor inactivator activity in human serum.
    Fantone J; Senior RM; Kreutzer DL; Jones M; Ward PA
    J Lab Clin Med; 1979 Jan; 93(1):17-24. PubMed ID: 759526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficiency of the chemotactic factor inactivator in human sera with 1 -antitrypsin deficiency.
    Ward PA; Talamo RC
    J Clin Invest; 1973 Feb; 52(2):516-9. PubMed ID: 4683887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.